The Efficacy of Urinary Continence in Patients Undergoing Robot-Assisted Radical Prostatectomy with Bladder-Prostatic Muscle Reconstruction and Bladder Neck Eversion Anastomosis.

Journal: Medicina (Kaunas, Lithuania)
Published Date:

Abstract

Background and Objectives: To evaluate the efficacy of bladder-prostatic muscle reconstruction and bladder neck eversion anastomosis in the recovery of urinary continence after robot-assisted radical prostatectomy (RARP). Materials and Methods: From January 2020 to May 2022, 69 patients who underwent RARP in our hospital were recruited. Thirty-seven patients underwent RARP with the Veil of Aphrodite technique (control group). On the basis of the control group, 32 patients underwent bladder-prostatic muscle reconstruction and bladder neck eversion anastomosis during RARP (observation group). The recovery of urinary continence was followed up at 24 h and 1, 4, 12, and 24 weeks after catheter removal. Results: There were no significant differences in operative time (127.76 ± 21.23 min vs. 118.85 ± 24.71 min), blood loss (118.27 ± 16.75 mL vs. 110.77 ± 19.63 mL), rate of leakage (3.13% vs. 2.70%), rate of positive surgical margin (6.25% vs. 10.81%), or postoperative Gleason score [7 (6−8) vs. 7 (7−8)] between the observation group and the control group (p > 0.05). After catheter removal, the rates of urinary continence at 24 h, 1 week, 4 weeks, 12 weeks, and 24 weeks were 46.88%, 68.75%, 84.38%, 90.63%, and 93.75% in the observation group, respectively. Meanwhile, the rates of urinary continence in the control group were 21.62%, 37.84%, 62.16%, 86.49%, and 91.89%, respectively. There was a significant difference between the two groups (p = 0.034), especially at 24 h, 1 week, and 4 weeks after catheter removal (p < 0.05). Conclusions: Bladder-prostatic muscle reconstruction and bladder neck eversion anastomosis were beneficial to the recovery of urinary continence after RARP, especially early urinary continence.

Authors

  • Yang Luan
    Clinical Medical College, Yangzhou University, Yangzhou 225009, China.
  • Xue-Fei Ding
    Clinical Medical College, Yangzhou University, Yangzhou 225009, China.
  • Sheng-Ming Lu
    Clinical Medical College, Yangzhou University, Yangzhou 225009, China.
  • Tian-Bao Huang
    Clinical Medical College, Yangzhou University, Yangzhou 225009, China.
  • Ji Chen
    Department of Population Health, New York University School of Medicine, New York, NY, United States.
  • Qin Xiao
    Clinical Medical College, Yangzhou University, Yangzhou 225009, China.
  • Li-Ping Wang
    Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No. 1 of East Banshan Road, Hangzhou, Zhejiang Province, China.
  • Hao-Peng Chen
    Clinical Medical College, Yangzhou University, Yangzhou 225009, China.
  • Yue-Xing Han
    Clinical Medical College, Yangzhou University, Yangzhou 225009, China.